Interaction of CR6 (GADD45γ) with Proliferating Cell Nuclear Antigen Impedes Negative Growth Control*

  1. Dan A. Liebermann
  1. From the Fels Institute for Cancer Research and Molecular Biology and the Department of Biochemistry, Temple University School of Medicine, Philadelphia, Pennsylvania 19140

Abstract

GADD45, MyD118, andCR6 (also termed GADD45α, β, and γ) comprise a family of genes that encode for related proteins playing important roles in negative growth control, including growth suppression. Data accumulated suggest that MyD118/GADD45/CR6 serve similar but not identical functions along different apoptotic and growth suppressive pathways. It is also apparent that individual members of the MyD118/GADD45/CR6 family are differentially induced by a variety of genetic and environmental stress agents. The MyD118, CR6, and GADD45 proteins were shown to predominantly localize within the cell nucleus. Recently, we have shown that both MyD118 and GADD45 interact with proliferating cell nuclear antigen (PCNA), a protein that plays a central role in DNA replication, DNA repair, and cell cycle progression, as well as with the universal cyclin-dependent kinase inhibitor p21. In this work we show that also CR6 interacts with PCNA and p21. Moreover, it is shown that CR6 interacts with PCNA via a domain that also mediates interaction of both GADD45 and MyD118 with PCNA. Importantly, evidence has been obtained that interaction of CR6 with PCNA impedes the function of this protein in negative growth control, similar to observations reported for MyD118 and GADD45 (1).

  • Abbreviations:
    MyD
    myeloid differentiation primary response
    CDK
    cyclin-dependent kinase
    aa
    amino acid(s)
    HA
    hemagglutinin
    β-Gal
    β-galactosidase
    PBS
    phosphate-buffered saline
    X-gal
    5-bromo-4-chloro-3-indolyl β-d-galactopyranoside, YTH, yeast two-hybrid
    YTHS
    YTH system
    PCNA
    proliferating cell nuclear antigen
    PAGE
    polyacrylamide gel electrophoresis
    IP
    immunoprecipitation
    • Received June 27, 2000.
    • Revision received September 14, 2000.
    Table of Contents

    Submit your work to JBC.

    You'll be in good company.